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Rationale: Approximately one-third of severe asthma patients are eligible for both anti-IgE and anti-IL-5/5R 
therapy. However, it is not clear whether one class of biologic works better than the other amongst patients 
eligible for both. Our aim was to describe the demographic and clinical characteristics of anti-IgE or anti-IL-
5/5R users who were eligible for both, and subsequently started either modality, using data from the 
International Severe Asthma Registry (ISAR; http;//isaregistries.org/). ISAR includes patients aged ≥18 years 
old at GINA Step 5 treatment, or with uncontrolled asthma at GINA Step 4. 
 
Methods: Patients eligible for both anti-IgE and anti-IL-5/5R, who subsequently started either modality from 
19 ISAR participating countries, recruited between January 2015 and September 2020, were included. They 
must have had ≥1 year of data prior to the biologic initiation date for study inclusion. Eligibility for both 
biologics was ascertained universally across all countries using frequent biologic-specific criteria: elevated 
blood eosinophil count, serum IgE, allergic-mediated asthma, and history of exacerbations at baseline. Pre-
biologic-initiation demographic and clinical variables were described for both anti-IgE and anti-IL-5/5R 
groups using data from 2015 onwards, when both therapies were available. Groups were compared using 
Pearson’s chi-square tests and t-tests. 
Results: Amongst 8826 patients, 1868 (21.2%) were considered eligible for both anti-IgE and anti-IL-5/5R. 
Of these, 659 started anti-IgE and 570 started anti-IL-5/5R after 2015, comprising the study cohort. 33.2% of 
anti-IgE and 45.7% of anti-IL-5/5R patients were also on long-term oral corticosteroids (LT-OCS) at the time 
of biologic initiation. Although differences were small, anti-IL-5/5R patients were slightly older, had later 
asthma onset, and were more likely to have uncontrolled asthma, ≥2 exacerbations, and FeNO >50 ppb 
(Table). Patients who received anti-IgE were more likely to be female, had a slightly higher mean BMI, and a 
higher prevalence of osteoporosis. These demographic, clinical, and co-morbidity patterns were similar 
irrespective of LT-OCS use, with the exception of osteoporosis prevalence, which was more elevated in the 
anti-IgE group versus anti-IL-5/5R for those on LT-OCS (45.0% [n=68/151] versus 15.2% [n=27/178]).  
Conclusion: Approximately one-fifth of severe asthma patients in ISAR were eligible for both anti-IgE and 
anti-IL-5/5R therapy. Most of these patients initiated biologic treatment. Anti-IL-5/5R eligible patients tended 
to have more severe disease pre-biologic initiation than their anti-IgE counterparts, which has implications 
when comparing effectiveness of these biologics. 
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OCS related Co-morbidities 












BMI: body mass index; Bx: biologic; FeNO: fractional exhaled nitric oxide; OCS: oral corticosteroid; SD: standard 
deviation;  
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